Compare DHI & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | IQV |
|---|---|---|
| Founded | 1978 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 36.4B |
| IPO Year | 1992 | 2013 |
| Metric | DHI | IQV |
|---|---|---|
| Price | $139.57 | $244.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $158.77 | ★ $236.93 |
| AVG Volume (30 Days) | ★ 2.8M | 1.2M |
| Earning Date | 01-20-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.57 | 7.30 |
| Revenue | ★ $34,250,400,000.00 | $15,904,000,000.00 |
| Revenue This Year | $0.40 | $6.15 |
| Revenue Next Year | $5.66 | $5.39 |
| P/E Ratio | ★ $12.49 | $32.93 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $110.44 | $134.65 |
| 52 Week High | $184.55 | $241.81 |
| Indicator | DHI | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 74.40 |
| Support Level | $143.18 | $221.78 |
| Resistance Level | $148.51 | $228.28 |
| Average True Range (ATR) | 3.33 | 4.55 |
| MACD | -0.76 | 1.69 |
| Stochastic Oscillator | 7.61 | 89.78 |
With operations in 126 markets across 36 states, D.R. Horton is the leading homebuilder in the United States. It mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.